Patrick H Maxwell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2556522/publications.pdf

Version: 2024-02-01

212 papers	37,690 citations	4960 84 h-index	2953 189 g-index
228 all docs	228 docs citations	228 times ranked	36242 citing authors

#	Article	IF	Citations
1	The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399, 271-275.	27.8	4,528
2	C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. Cell, 2001, 107, 43-54.	28.9	3,293
3	Role of HIF-1Î± in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 1998, 394, 485-490.	27.8	2,565
4	The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1Î± and HIF-2Î± in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. American Journal of Pathology, 2000, 157, 411-421.	3.8	1,191
5	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	27.8	1,041
6	Hypoxia Inducible Factor-Î± Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein. Journal of Biological Chemistry, 2000, 275, 25733-25741.	3.4	945
7	Independent function of two destruction domains in hypoxia-inducible factor-Î± chains activated by prolyl hydroxylation. EMBO Journal, 2001, 20, 5197-5206.	7.8	945
8	Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma. Molecular and Cellular Biology, 2005, 25, 5675-5686.	2.3	847
9	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	27.8	756
10	Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization. Cell, 2009, 136, 839-851.	28.9	727
11	Structural basis for the recognition of hydroxyproline in HIF-1Î± by pVHL. Nature, 2002, 417, 975-978.	27.8	651
12	Widespread, hypoxiaâ€inducible expression of HIFâ€2Î± in distinct cell populations of different organs. FASEB Journal, 2003, 17, 271-273.	0.5	640
13	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	27.8	549
14	Expression of Hypoxia-Inducible Factor-1Î± and -2Î± in Hypoxic and Ischemic Rat Kidneys. Journal of the American Society of Nephrology: JASN, 2002, 13, 1721-1732.	6.1	521
15	Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science, 2018, 361, 594-599.	12.6	511
16	Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling. Cancer Cell, 2011, 20, 524-537.	16.8	494
17	Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genetics, 2002, 32, 614-621.	21.4	469
18	HIF activation identifies early lesions in VHL kidneys. Cancer Cell, 2002, 1, 459-468.	16.8	456

#	Article	IF	Citations
19	Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature, 2016, 537, 544-547.	27.8	443
20	Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays. Cell, 2022, 185, 1777-1792.e21.	28.9	437
21	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics, 2008, 40, 170-180.	21.4	433
22	Activation of the HIF pathway in cancer. Current Opinion in Genetics and Development, 2001, 11, 293-299.	3.3	363
23	Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics, 2001, 10, 1029-1038.	2.9	343
24	Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney International, 1993, 44, 1149-1162.	5.2	341
25	Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. Journal of Experimental Medicine, 2006, 203, 1519-1532.	8.5	338
26	Targeting tumors through the HIF system. Nature Medicine, 2000, 6, 1315-1316.	30.7	310
27	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, The, 2010, 376, 794-801.	13.7	298
28	Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO Journal, 2006, 25, 5603-5613.	7.8	294
29	A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 654-659.	7.1	292
30	Oxygen sensors and angiogenesis. Seminars in Cell and Developmental Biology, 2002, 13, 29-37.	5.0	288
31	Heterozygous deficiency of hypoxia-inducible factorâ€“2Î± protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. Journal of Clinical Investigation, 2003, 111, 1519-1527.	8.2	267
32	Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney International, 2009, 75, 976-981.	5.2	266
33	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature, 2011, 479, 122-126.	27.8	265
34	Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor. Cancer Research, 2006, 66, 3567-3575.	0.9	248
35	Inhibition of Hypoxia Inducible Factor Hydroxylases Protects Against Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 39-46.	6.1	246
36	Genetic loci influencing kidney function and chronic kidney disease. Nature Genetics, 2010, 42, 373-375.	21.4	246

#	Article	IF	Citations
37	Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 2000, 19, 6297-6305.	5.9	245
38	Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell, 2010, 141, 178-190.	28.9	243
39	HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nature Reviews Nephrology, 2016, 12, 157-168.	9.6	234
40	HLA Has Strongest Association with IgA Nephropathy in Genome-Wide Analysis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1791-1797.	6.1	233
41	Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet, The, 2015, 385, 1993-2002.	13.7	227
42	Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nature Genetics, 2009, 41, 1170-1172.	21.4	217
43	HIF-1, An Oxygen and Metal Responsive Transcription Factor. Cancer Biology and Therapy, 2004, 3, 29-35.	3.4	210
44	Xenon Preconditioning Protects against Renal Ischemic-Reperfusion Injury via HIF-1Î± Activation. Journal of the American Society of Nephrology: JASN, 2009, 20, 713-720.	6.1	198
45	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	13.7	194
46	Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Research, 2005, 65, 11520-11528.	0.9	187
47	Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Research, 2002, 62, 2957-61.	0.9	186
48	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
49	Abnormal Sympathoadrenal Development and Systemic Hypotension in PHD3^{â^'/â^'} Mice. Molecular and Cellular Biology, 2008, 28, 3386-3400.	2.3	176
50	Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function. Gastroenterology, 2010, 139, 2093-2101.	1.3	175
51	Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 Î±-Subunit (HIF-1Î±). Journal of Biological Chemistry, 1998, 273, 8360-8368.	3.4	174
52	Genetic evidence for a tumor suppressor role of HIF-2Î±. Cancer Cell, 2005, 8, 131-141.	16.8	174
53	HIF-1Î± metabolically controls collagen synthesis and modification in chondrocytes. Nature, 2019, 565, 511-515.	27.8	169
54	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	5.2	167

#	Article	IF	Citations
55	Mutation of von Hippelâ€“Lindau Tumour Suppressor and Human Cardiopulmonary Physiology. PLoS Medicine, 2006, 3, e290.	8.4	163
56	The HIF pathway in cancer. Seminars in Cell and Developmental Biology, 2005, 16, 523-530.	5.0	162
57	Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2010, 95, 505-508.	3.5	159
58	Targeted Inactivation of Fh1 Causes Proliferative Renal Cyst Development and Activation of the Hypoxia Pathway. Cancer Cell, 2007, 11, 311-319.	16.8	158
59	Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein. Journal of the American Society of Nephrology: JASN, 2006, 17, 1801-1806.	6.1	148
60	Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. Journal of Clinical Investigation, 2011, 121, 1053-1063.	8.2	147
61	Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2Î± mutation. Blood, 2008, 112, 919-921.	1.4	143
62	HIF-1Î± Promotes Glutamine-Mediated Redox Homeostasis and Glycogen-Dependent Bioenergetics to Support Postimplantation Bone Cell Survival. Cell Metabolism, 2016, 23, 265-279.	16.2	142
63	The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1Î± in renal cell carcinoma. Oncogene, 2001, 20, 5067-5074.	5.9	141
64	Hypoxiaâ€inducible factor as a physiological regulator. Experimental Physiology, 2005, 90, 791-797.	2.0	137
65	HIF-1 reduces ischaemiaâ€“reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovascular Research, 2014, 104, 24-36.	3.8	136
66	Familial C3 Glomerulopathy Associated with CFHR5 Mutations. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1436-1446.	4.5	124
67	HIF-1. Journal of the American Society of Nephrology: JASN, 2003, 14, 2712-2722.	6.1	120
68	The hypoxia factor Hif-1Î± controls neural crest chemotaxis and epithelial to mesenchymal transition. Journal of Cell Biology, 2013, 201, 759-776.	5.2	119
69	Persistent induction of HIFâ€1Î± and â€2Î± in cardiomyocytes and stromal cells of ischemic myocardium. FASEB Journal, 2004, 18, 1415-1417.	0.5	118
70	The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress. Molecular and Cellular Biology, 2008, 28, 2701-2717.	2.3	115
71	Loss or Silencing of the PHD1 Prolyl Hydroxylase Protects Livers of Mice Against Ischemia/Reperfusion Injury. Gastroenterology, 2010, 138, 1143-1154.e2.	1.3	108
72	Deletion of the von Hippelâ€“Lindau gene in pancreatic Î² cells impairs glucose homeostasis in mice. Journal of Clinical Investigation, 2009, 119, 125-35.	8.2	108

#	Article	IF	Citations
73	Peptide blockade of HIFÂ degradation modulates cellular metabolism and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10423-10428.	7.1	101
74	The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1547-1550.	2.2	97
75	PTEN CAN FUNCTION AS A TUMOR SUPPRESSOR IN CLEAR CELL RENAL CARCINOMA. Journal of Urology, 2009, 181, 35-36.	0.4	97
76	Hypoxia-inducible Factor-2Î± (HIF-2Î±) Is Involved in the Apoptotic Response to Hypoglycemia but Not to Hypoxia. Journal of Biological Chemistry, 2001, 276, 39192-39196.	3.4	96
77	HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. Journal of Molecular and Cellular Cardiology, 2006, 41, 68-77.	1.9	96
78	The hypoxia response pathway and Î²â€cell function. Diabetes, Obesity and Metabolism, 2010, 12, 159-167.	4.4	95
79	Prolyl Hydroxylase Domain Inhibitors: A Route to HIF Activation and Neuroprotection. Antioxidants and Redox Signaling, 2010, 12, 459-480.	5.4	92
80	Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. Nature Communications, 2018, 9, 2557.	12.8	92
81	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	5.2	91
82	HIF-1alpha and HIF-2alpha Are Differentially Activated in Distinct Cell Populations in Retinal Ischaemia. PLoS ONE, 2010, 5, e11103.	2.5	90
83	Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. British Journal of Cancer, 2004, 90, 1235-1243.	6.4	89
84	Hypoxia-Inducible Transcription Factors Stabilization in the Thick Ascending Limb Protects against Ischemic Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2011, 22, 2004-2015.	6.1	88
85	Rolling back human pluripotent stem cells to an eight-cell embryo-like stage. Nature, 2022, 605, 315-324.	27.8	87
86	Sites of erythropoietin production. Kidney International, 1997, 51, 393-401.	5.2	86
87	Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood, 2002, 100, 2406-2413.	1.4	86
88	Cardiopulmonary function in two human disorders of the hypoxiaâ€inducible factor (HIF) pathway: von Hippelâ€Lindau disease and HIFâ€2Î± gainâ€ofâ€function mutation. FASEB Journal, 2011, 25, 2001-2011.	0.5	86
89	Role of Gas6 in erythropoiesis and anemia in mice. Journal of Clinical Investigation, 2008, 118, 583-96.	8.2	84
90	Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. Journal of Clinical Investigation, 2012, 122, 600-611.	8.2	82

#	Article	IF	Citations
91	Cell transcriptomic atlas of the non-human primate Macaca fascicularis. Nature, 2022, 604, 723-731.	27.8	81
92	Renal Tubular HIF-2Î± Expression Requires VHL Inactivation and Causes Fibrosis and Cysts. PLoS ONE, 2012, 7, e31034.	2.5	78
93	Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors. PLoS ONE, 2009, 4, e7875.	2.5	76
94	Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood, 2007, 109, 4742-4752.	1.4	71
95	Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. Journal of Clinical Investigation, 2017, 127, 3407-3420.	8.2	71
96	The interstitial response to renal injury: Fibroblastâ€“like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney International, 1997, 52, 715-724.	5.2	70
97	Regulation of Renal Epithelial Tight Junctions by the von Hippel-Lindau Tumor Suppressor Gene Involves Occludin and Claudin 1 and Is Independent of E-Cadherin. Molecular Biology of the Cell, 2009, 20, 1089-1101.	2.1	70
98	Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clinical Cancer Research, 2002, 8, 471-80.	7.0	70
99	Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. Journal of Applied Physiology, 2000, 89, 680-686.	2.5	63
100	Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood, 2006, 108, 3176-3178.	1.4	63
101	Expression Profiling in Progressive Stages of Fumarate-Hydratase Deficiency: The Contribution of Metabolic Changes to Tumorigenesis. Cancer Research, 2010, 70, 9153-9165.	0.9	63
102	Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nature Communications, 2014, 5, 5582.	12.8	61
103	VHL Inactivation Induces HEF1 and Aurora Kinase A. Journal of the American Society of Nephrology: JASN, 2010, 21, 2041-2046.	6.1	60
104	HIF and oxygen sensing; as important to life as the air we breathe?. Annals of Medicine, 2003, 35, 183-190.	3.8	58
105	HIF, a missing link between metabolism and cancer. Nature Medicine, 2005, 11, 1047-1048.	30.7	58
106	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology, 2017, 19, 1093-1104.	10.3	58
107	Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families. Human Mutation, 2005, 25, 135-141.	2.5	57
108	Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. ELife, 2021, 10, .	6.0	57

#	Article	IF	Citations
109	Hypoxia and Upregulation of Hypoxia-Inducible Factor 1Î± Stimulate Venous Thrombus Recanalization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2443-2451.	2.4	56
110	Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics, 2017, 13, e1006620.	3.5	52
111	Cezanne Regulates Inflammatory Responses to Hypoxia in Endothelial Cells by Targeting TRAF6 for Deubiquitination. Circulation Research, 2013, 112, 1583-1591.	4.5	51
112	Family-Based Association Study Showing that Immunoglobulin A Nephropathy Is Associated with the Polymorphisms 2093C and 2180T in the 3' Untranslated Region of the Megsin Gene. Journal of the American Society of Nephrology: JASN, 2004, 15, 1739-1743.	6.1	45
113	Reactivation ofSnailGenes in Renal Fibrosis and Carcinomas: A Process of Reversed Embryogenesis?. Cell Cycle, 2007, 6, 638-642.	2.6	45
114	The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity. Journal of Biological Chemistry, 2014, 289, 3339-3351.	3.4	45
115	Expression of Hypoxia-Inducible Factors in Normal Human Lung Development. Pediatric and Developmental Pathology, 2008, 11, 193-199.	1.0	44
116	The HIF Pathway: Implications for Patterns of Gene Expression in Cancer. Novartis Foundation Symposium, 2001, 240, 212-231.	1.1	44
117	HIF-1â€™s Relationship to Oxygen: Simple yet Sophisticated. Cell Cycle, 2004, 3, 151-154.	2.6	43
118	The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. Journal of Molecular Medicine, 2008, 86, 1329-1339.	3.9	43
119	Oxygen regulated gene expression: Erythropoietin as a model system. Kidney International, 1997, 51, 514-526.	5.2	42
120	Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood, 2011, 117, 3699-3701.	1.4	41
121	Dynamic regulation of hypoxia-inducible factor-1Î± activity is essential for normal B cell development. Nature Immunology, 2020, 21, 1408-1420.	14.5	40
122	Effects of VHL Deficiency on Endolymphatic Duct and Sac. Cancer Research, 2005, 65, 10847-10853.	0.9	39
123	Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. Journal of Pathology, 2006, 210, 32-41.	4.5	39
124	Organ-Specific Collagen Expression: Implications for Renal Disease. Nephron Experimental Nephrology, 2006, 102, e71-e75.	2.2	38
125	The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes. Nature Genetics, 2021, 53, 1022-1035.	21.4	38
126	Evolution of VHL tumourigenesis in nerve root tissue. Journal of Pathology, 2006, 210, 374-382.	4.5	37

#	Article	IF	Citations
127	Variations within oxygen-regulated gene expression in humans. Journal of Applied Physiology, 2009, 106, 212-220.	2.5	37
128	Hypoxia and B cells. Experimental Cell Research, 2017, 356, 197-203.	2.6	36
129	Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine. Scientific Reports, 2017, 7, 9214.	3.3	36
130	Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. International Journal of Cancer, 2007, 121, 2434-2442.	5.1	34
131	Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodialysis International, 2007, 11, 430-434.	0.9	34
132	Endogenous Erythropoietin Protects Neuroretinal Function in Ischemic Retinopathy. American Journal of Pathology, 2012, 180, 1726-1739.	3.8	33
133	Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney International, 2002, 62, 1395-1401.	5.2	32
134	Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R130.	3.5	32
135	Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Scientific Reports, 2016, 6, 22950.	3.3	32
136	Hypoxia and oxidative stress in breast cancer Hypoxia signalling pathways. Breast Cancer Research, 2001, 3, 313-7.	5.0	30
137	A common pathway for genetic events leading to pheochromocytoma. Cancer Cell, 2005, 8, 91-93.	16.8	30
138	The role of HIF in immunity. International Journal of Biochemistry and Cell Biology, 2010, 42, 486-494.	2.8	30
139	Developmentally arrested structures preceding cerebellar tumors in von Hippelâ€“Lindau disease. Modern Pathology, 2011, 24, 1023-1030.	5.5	30
140	Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor. Journal of Biological Chemistry, 2001, 276, 44323-44330.	3.4	29
141	The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor Î±. Advances in Enzyme Regulation, 2004, 44, 75-92.	2.6	28
142	Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences. Kidney International, 2013, 84, 667-681.	5.2	28
143	Progression of Epididymal Maldevelopment Into Hamartoma-like Neoplasia in VHL Disease. Neoplasia, 2008, 10, 1146-1153.	5.3	26
144	Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Molecular Cancer, 2011, 10, 89.	19.2	26

#	Article	IF	Citations
145	Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer, 2020, 20, 469.	2.6	25
146	A novelCOL4A1frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen. Nephrology Dialysis Transplantation, 2016, 31, 1908-1914.	0.7	24
147	Von Hippel-Lindau protein in the RPE is essential for normal ocular growth and vascular development. Development (Cambridge), 2012, 139, 2340-2350.	2.5	23
148	VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function. Frontiers in Oncology, 2018, 8, 388.	2.8	23
149	C3 glomerulonephritis and CFHR5 nephropathy. Nephrology Dialysis Transplantation, 2013, 28, 282-288.	0.7	22
150	Oxygen homeostasis and cancer: insights from a rare disease. Clinical Medicine, 2002, 2, 356-362.	1.9	21
151	Dimethyloxalylglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms. Laboratory Investigation, 2011, 91, 1684-1694.	3.7	20
152	A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population. PLoS ONE, 2017, 12, e0174274.	2.5	20
153	Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney International, 2017, 92, 900-908.	5.2	18
154	HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle, 2004, 3, 156-9.	2.6	18
155	Evidence for hypoxiaâ€induced neuronalâ€toâ€chromaffin metaplasia in neuroblastoma. FASEB Journal, 2003, 17, 598-609.	0.5	17
156	Copy number profiling in von hippelâ€lindau disease renal cell carcinoma. Genes Chromosomes and Cancer, 2011, 50, 479-488.	2.8	17
157	Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma. Oncotarget, 2016, 7, 24111-24124.	1.8	16
158	Regulation of the HIF pathway: enzymatic hydroxylation of a conserved prolyl residue in hypoxia-inducible factor alpha subunits governs capture by the pVHL E3 ubiquitin ligase complex. Advances in Enzyme Regulation, 2002, 42, 333-347.	2.6	15
159	Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression. Journal of Molecular Medicine, 2009, 87, 871-877.	3.9	15
160	Microchimeric Fetal Cells Are Recruited to Maternal Kidney following Injury and Activate Collagen Type I Transcription. Cells Tissues Organs, 2011, 193, 379-392.	2.3	15
161	Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1. Journal of Biological Chemistry, 2017, 292, 4755-4763.	3.4	15
162	The impact of hypoxia on B cells in COVID-19. EBioMedicine, 2022, 77, 103878.	6.1	15

#	Article	IF	Citations
163	Association of MEGSIN 2093Câ€“2180T haplotype at the 3â€² untranslated region with disease severity and progression of IgA nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 1570-1574.	0.7	13
164	Dent Disease in Chinese Children and Findings from Heterozygous Mothers: Phenotypic Heterogeneity, Fetal Growth, and 10 Novel Mutations. Journal of Pediatrics, 2016, 174, 204-210.e1.	1.8	13
165	A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Reports, 2009, 2009, bcr0820080732-bcr0820080732.	0.5	13
166	Regulation of expression of the erythropoietin gene. Current Opinion in Hematology, 1998, 5, 166-170.	2.5	12
167	Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues. Journal of Pathology, 2011, 225, 1-3.	4.5	12
168	Incidence of End-Stage Renal Disease in the Turkish-Cypriot Population of Northern Cyprus: A Population Based Study. PLoS ONE, 2013, 8, e54394.	2.5	12
169	Manifesto for a healthy and health-creating society. Lancet, The, 2016, 388, e24-e27.	13.7	11
170	Epistatic Role of the MYH9/APOL1 Region on Familial Hematuria Genes. PLoS ONE, 2013, 8, e57925.	2.5	11
171	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.7	10
172	Cardiopulmonary phenotype associated with humanPHD2mutation. Physiological Reports, 2017, 5, e13224.	1.7	10
173	Mass testing of university students for covid-19. BMJ, The, 2021, 375, n2388.	6.0	10
174	Differentiation in Neuroblastoma: Diffusion-Limited Hypoxia Induces Neuro-Endocrine Secretory Protein 55 and Other Markers of a Chromaffin Phenotype. PLoS ONE, 2010, 5, e12825.	2.5	10
175	Genetic Studies of IgA Nephropathy. Nephron Experimental Nephrology, 2006, 102, e76-e80.	2.2	9
176	A new approach to treating renal anaemia. Nature Reviews Nephrology, 2019, 15, 731-732.	9.6	9
177	What happens to clinical training fellows? A retrospective study of the 20â€…years outcome of a Medical Research Council UK cohort. BMJ Open, 2012, 2, e001792.	1.9	8
178	Tumor strengths and frailties: Aspiring to prevent colon cancer. Nature Medicine, 2012, 18, 32-33.	30.7	7
179	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience, 2022, 25, 103971.	4.1	7
180	Manipulation of oxygen tensions forin vitrocell culture using a hypoxic workstation. Expert Review of Proteomics, 2005, 2, 307-314.	3.0	6

#	Article	IF	Citations
181	Identification of novel VHL regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells. Advances in Enzyme Regulation, 2009, 49, 43-52.	2.6	6
182	Genetic insights into the hypoxia-inducible factor (HIF) pathway. Advances in Enzyme Regulation, 2007, 47, 288-306.	2.6	5
183	Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. Nephrology Dialysis Transplantation, 2010, 25, 1547-1554.	0.7	5
184	Combinatorial Conflicting Homozygosity (CCH) analysis enables the rapid identification of shared genomic regions in the presence of multiple phenocopies. BMC Genomics, 2015, 16, 163.	2.8	5
185	Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-hydroxylase and Inhibited by Some PHD Inhibitors. Kidney360, 2020, 1, 447-457.	2.1	4
186	Dialysis Survivors: Clinical Status of Patients on Treatment for More than 10 Years. Nephron Clinical Practice, 2008, 108, c207-c212.	2.3	3
187	End-stage renal failure associated with congenital deafness. CKJ: Clinical Kidney Journal, 2008, 1, 171-175.	2.9	3
188	Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer. Nature Reviews Urology, 2021, 18, 516-517.	3.8	3
189	Guiding hands of our teachers. Lancet, The, 2001, 357, 480.	13.7	2
190	Correction of severe anaemia using immuno-regulated gene therapy is achieved by restoring the early erythroblast compartment. British Journal of Haematology, 2006, 132, 608-614.	2.5	2
191	A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis. Molecular Immunology, 2009, 46, 2822.	2.2	2
192	Regulation of HIF-1 by Oxygen. , 2003, , 47-64.		2
193	Improving the efficiency and effectiveness of an industrial SARS-CoV-2 diagnostic facility. Scientific Reports, 2022, 12, 3114.	3.3	2
194	Genetic and structural analyses suggest that a novel SPG3A mutation causes severe phenotypes of hereditary spastic paraplegia. Science Bulletin, 2006, 51, 2038-2040.	1.7	1
195	Response to â€˜Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal diseaseâ€™. Kidney International, 2009, 76, 1116.	5.2	1
196	Response to â€˜Hepcidin levels in patients with renal diseaseâ€™. Kidney International, 2009, 76, 680-681.	5.2	1
197	Response to â€˜The utility of multivariate analysis in the study of hepcidinâ€™. Kidney International, 2009, 76, 912-913.	5.2	1
198	Is it rejection? Be on the lookout for â€˜decoysâ€™. Nephrology Dialysis Transplantation, 2005, 20, 2002-2004.	0.7	0

#	Article	IF	Citations
199	INACTIVATION OF THE PHOSPHATASE AND TENSIN HOMOLOG (PTEN) TUMOR SUPPRESSOR CONTRIBUTES TO TUMOR CHARACTERISTICS OF 786-O CLEAR CELL RENAL CARCINOMA CELLS. Journal of Urology, 2008, 179, 89-89.	0.4	0
200	Oxygen availability sHIFts the cell cycle. Cell Cycle, 2009, 8, 1305-1307.	2.6	0
201	Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. Nephrology Dialysis Transplantation, 2010, 25, 1-1.	0.7	0
202	Prolyl Hydroxylase Phd3 Is Essential For Hypoxic Regulation Of Neutrophilic Inflammation. , 2011, , .		0
203	Increasing evidence that genetic variation in Complement factor H related 5 (CFHR5) causes disease: A commentary on â€˜Atypical haemolytic uremic syndrome and genetic aberrations in the complement factor-H-related 5 geneâ€™. Journal of Human Genetics, 2012, 57, 473-474.	2.3	0
204	SP014A NOVEL COL4A1 FRAMESHIFT MUTATION AND KIDNEY DISEASE WITHOUT EXTRA-RENAL INVOLVEMENT IN A LARGE TURKISH CYPRIOT FAMILY. Nephrology Dialysis Transplantation, 2015, 30, iii385-iii385.	0.7	0
205	EP-2298: Hypoxia inducible factor 1Î± confers androgen independence in prostate cancer. Radiotherapy and Oncology, 2018, 127, S1268.	0.6	0
206	Critical Amplification by Gas6 of the Epo-Dependent Erythropoietic Response to Anemia: Novel Opportunities for Anemia Treatment.. Blood, 2004, 104, 459-459.	1.4	0
207	622: Von Hippel-Lindau Inactivation Downregulates the Cell-Cell Adhesion Molecule E Cadherin in Renal Cancer Cells. Journal of Urology, 2005, 173, 170-170.	0.4	0
208	374: The Identity of the Angiogenic Switch in Renal Cancer. Journal of Urology, 2006, 175, 122-123.	0.4	0
209	368: The Cell of Origin of Clear Cell Renal Carcinoma - Re-Visited. Journal of Urology, 2006, 175, 120-121.	0.4	0
210	Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. Journal of Cell Biology, 2006, 173, i11-i11.	5.2	0
211	Genetic Contribution to IgA Nephropathy. , 2009, , 21-36.		0
212	The Molecular Genetics and Pathology of Renal Cell Carcinoma. , 2010, , 360-373.		0